Journal: Drug metabolism and pharmacokinetics

Article Title: Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.

PMID/MRN: 27829538

Publication Date: 2016-Dec-12

Abstract:

Mirabegron, the first selective ? 3 -adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinetic drug interaction between mirabegron and tolterodine, another OAB drug and a sensitive substrate of CYP2D6. Tolterodine 4Êmg was orally administered from Days 1-7 and co-administered with mirabegron 50Êmg from Days 8-14. Mirabegron 50Êmg increased maximum concentration (C max ) and area under the concentration-time curve from zero to 24Êh after dosing (AUC 24h ) of tolterodine by 2.06-fold (90% confidence interval [CI] 1.81, 2.34) and 1.86-fold (90% CI 1.60, 2.16), respectively, and increased C max and AUC 24h of the metabolite 5-hydroxymethyl tolterodine by 1.36-fold (90% CI 1.26, 1.47) and 1.25-fold (90% CI 1.15, 1.37), respectively. This suggested a weak pharmacokinetic drug interaction between mirabegron and tolterodine. Mean change from baseline of Fridericia's QT correction formula (?QTcF) was slightly higher on Day 14 than on Day 7. No subject had QTcF >480 msec or ?QTcF >60Êmsec. All the treatment-emergent adverse events were mild. Mirabegron 50Êmg was considered to be safe and well tolerated when coadministered with tolterodine 4Êmg in healthy postmenopausal female volunteers. Copyright © 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.